Table 2.

Univariate Analysis of Factors Associated with Disease-free Survival.

Characteristic	No. of Patients	3-year DFS, %	5-year DFS, %	P Value	HR	95% CI
Sex
Male	88	34	30	.82	1.04	.72 – 1.50
Female	83	32	27
Age
<60 years	88	32	30	.68	.92	.64 – 1.34
≥60 years	83	34	26
Synchronous CLM
Yes	106	37	30	.56	.92	.63 – 1.34
No	65	26	26
Primary tumor site
Colon	123	31	30	.71	.93	.64 – 1.35
Rectum	48	36	27
Primary tumor lymph node status
Positive	99	30	26	.25	1.24	.85 – 1.81
Negative	72	37	32
Chemotherapy
Irinotecan	60	25	21	.088	1.39	.95 – 2.02
Oxaliplatin	111	37	33
Bevacizumab
Yes	75	37	35	.38	.85	.59 – 1.23
No	96	29	24
Months of chemotherapy
≤3	85	39	35	.056	1.43	.99 – 2.07
>3	86	28	21
CEA level ≥5 ng/mLΩ
Yes	73	21	17	.005	1.69	1.17 – 2.44
No	70	44	38
No. of CLM
<3	111	35	30	.09	1.46	.94 – 2.26
≥3	60	30	25
Diameter of largest CLM ≥3 cm
Yes	82	29	25	.17	1.28	.89 – 1.85
No	89	37	31
Pathologic response
Complete	14	77	77
Major	84	32	31	.001†	6.81	2.13– 21.8
Minor	73	26	18	.049‡	4.69	1.47 – 15
Tumor thickness at TNI
<0.5	35	58	58
≥0.5 mm and <5 mm	97	31	24	<.001§	4.54	2.41 – 8.45
≥5 mm mm	39	15	11	.003**	2.39	1.34 – 4.27
Positive margin
No	163	35	30
Yes	8	0	0	.003	2.86	1.37 – 5.94

Abbreviations: HR, hazard ratio; CI, confidence interval; CEA, carcinoembryonic antigen; CLM, colorectal liver metastases; HR, hazard ratio; TNI, tumor–normal tissue interface.

^†Patients with complete vs major vs minor response.

^‡Patients with major vs minor response.

^§Patients with TNI thickness <0.5 mm vs ≥0.5 mm and <5 mm vs ≥5 mm.

^**Patients with TNI thickness ≥0.5 mm and <5 mm vs ≥5 mm.

^ΩMissing data for 28 patients.